Cefar URO - Symptomatic Treatment of Overactive Bladder
NCT: NCT06659536 · RECRUITING
Brief Summary
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling. The Cefar URO device features four pre-set programs (P1, P2, P3 and P4) and three custom programs. Although supporting data on the preset programs P1, P2, P3 are available for the clinically equivalent UROstim2 device, program P4 is unique to Cefar URO. Program P4 utilizes the parameters 20Hz and 200μs which are commonly reported in the literature for the stated indications but for which no data is available for the clinically equivalent UROstim2 device. The present study is therefore aimed to cover this data gap.
Frequently Asked Questions
What is Cefar URO - Symptomatic Treatment of Overactive Bladder?
Cefar URO - Symptomatic Treatment of Overactive Bladder is a clinical trial registered under NCT06659536. Current status: RECRUITING.
What is the status of NCT06659536?
The current status of NCT06659536 (Cefar URO - Symptomatic Treatment of Overactive Bladder) is: RECRUITING.
When did Cefar URO - Symptomatic Treatment of Overactive Bladder start?
Cefar URO - Symptomatic Treatment of Overactive Bladder started on 2026-01-19.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.